[Diagnostic and therapeutic biomarkers for lung cancer patients].

Abstract

Identification of sensitive biomarkers predictive of diagnosis, prognosis and drug sensitivity could have a clinically significant impact on non-small cell lung cancer (NSCLC) treatment strategies. Recently, molecular-targeted therapies have been developed for NSCLC treatment. NSCLC patients with epidermal growth factor receptor (EGFR) gene mutations have shown a dramatic response to EGFR tyrosine kinase inhibitors (EGFR-TKI) such as gefitinib and erlotinib. In addition, target therapies against echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) fusion protein present in approximately 5% of the Japanese patients with adenocarcinomas are currently under development. In this paper, we reviewed diagnostic and therapeutic biomarkers for lung cancer patients.

• Authors: Masahiro Seike, Akihiko Gemma
• Journal: Nihon rinsho. Japanese journal of clinical medicine (Nihon Rinsho) Vol. 70 Issue 5 Pg. 809-15 (May 2012) ISSN: 0047-1852 [Print] Japan
• PMID: 22620005 (Publication Type: Journal Article, Review)

Chemical References

• Biomarkers, Tumor
• EML4-ALK fusion protein, human
• Oncogene Proteins, Fusion
• ErbB Receptors

Topics

• Adenocarcinoma (drug therapy)
• Biomarkers, Tumor (analysis)
• Carcinoma, Non-Small-Cell Lung (drug therapy, genetics)
• ErbB Receptors (antagonists & inhibitors)
• Genes, erbB-1 (genetics)
• Humans
• Lung Neoplasms (drug therapy, genetics)
• Oncogene Proteins, Fusion (analysis)